Who is sponsoring NCT03115489?

NCT03115489 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT03115489?

Interventions in NCT03115489: Traditional Treatment (Group T), Ketamine Infusion (Group K).

What condition does NCT03115489 study?

NCT03115489 studies Refractory Epilepsy.

Is NCT03115489 still recruiting?

NCT03115489 is currently withdrawn. Last updated 21 May 2021.

Last reviewed 2021-05-21 · How we verify

NCT03115489

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus

Withdrawn Phase 2, PHASE3 Last updated 21 May 2021

What this trial tests

Phase 2, PHASE3 trial testing Traditional Treatment (Group T) in Refractory Epilepsy. Withdrawn.

Timeline

4 May 2017

Primary endpoint
31 December 2019

18 May 2021

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	Phase 2, PHASE3
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Start date	4 May 2017
Primary completion	31 December 2019
Estimated completion	18 May 2021
Sites	1 location across United States

Drugs / interventions tested

Traditional Treatment (Group T) — full drug profile →
Ketamine Infusion (Group K) — full drug profile →

Conditions studied

Refractory Epilepsy — all drugs for Refractory Epilepsy →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 18 to 100, any sex, with Refractory Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study will investigate the efficacy of the N-methyl-D-aspartate receptor antagonist ketamine as a first line agent in refractory status epilepticus versus traditional general anesthetic agents used for burst suppression that target the gamma-aminobutyric acid adrenergic receptors.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Ketamine to treat super-refractory status epilepticus.
Alkhachroum A, Der-Nigoghossian CA, Mathews E, Massad N, et al · · 2020 · cited 82× · PMID 32873691 · DOI 10.1212/wnl.0000000000010611
Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee.
Vossler DG, Bainbridge JL, Boggs JG, Novotny EJ, et al · · 2020 · cited 75× · PMID 32822230 · DOI 10.1177/1535759720928269
Ketamine for Refractory Status Epilepticus: A Systematic Review.
Rosati A, De Masi S, Guerrini R. · · 2018 · cited 63× · PMID 30232735 · DOI 10.1007/s40263-018-0569-6
Ketamine in adult super-refractory status epilepticus: Efficacy analysis on a prospective registry.
Caranzano L, Novy J, Rossetti AO. · · 2022 · cited 19× · PMID 35274736 · DOI 10.1111/ane.13610
Repurposing Potential of Ketamine: Opportunities and Challenges.
Gautam CS, Mahajan SS, Sharma J, Singh H, et al · · 2020 · cited 19× · PMID 31997862 · DOI 10.4103/ijpsym.ijpsym_228_19
A new class of peptides from wasp venom: a pathway to antiepileptic/neuroprotective drugs.
Mortari MR, Cunha AOS, Dos Anjos LC, Amaral HO, et al · · 2023 · cited 6× · PMID 36844150 · DOI 10.1093/braincomms/fcad016

Verify or expand the search:

Other recruiting trials for Refractory Epilepsy

Currently open trials in the same condition.

NCT06425029 — Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application · NA · recruiting
NCT06524479 — Investigating the Functional Characteristics During Wakefulness and Sleep Based on SEEG · NA · recruiting
NCT06241963 — High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy · NA · recruiting
NCT06396494 — An Automated Navigation System for Deep Brain Electrode Implantation · active not recruiting
NCT05493722 — Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy · EARLY_PHASE1 · recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03115489 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 21 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03115489.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing